Drug Profile
Doxycycline hyclate - Aqua Pharmaceuticals
Alternative Names: ACTICLATE; ACTICLATE CAP; AQ101; Doxycycline hyclate USP; MonodoxLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Aqua Pharmaceuticals
- Class Antibacterials; Collagenases; Skin disorder therapies; Tetracyclines
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Acne; Amoebiasis; Anthrax; Bacterial infections; Borrelia infections; Brucellosis; Campylobacter infections; Chancroid; Chlamydial infections; Cholera; Clostridium infections; Escherichia coli infections; Fusobacterium infections; Gonorrhoea; Gram-negative infections; Gram-positive infections; Haemophilus infections; Klebsiella infections; Listeria infections; Malaria; Plague; Pneumonia; Rickettsia infections; Shigella infections; Urethritis
Most Recent Events
- 26 Apr 2016 Registered for Anthrax, Borrelia infections, Brucellosis, Campylobacter infections, Chancroid, Chlamydial infections, Cholera, Escherichia coli infections, Gonorrhoea, Haemophilus infections, Klebsiella infections, Plague, Pneumonia, Rickettsia infections, Shigella infections and Urethritis, Clostridium infections (treatment-experienced), Listeria infections (treatment-experienced) and Malaria (treatment-experienced), Acne (adjunctive treatment), Gram-positive infections, Gram-negative infections and Bacterial infections in USA (PO, Capsule)
- 31 Aug 2014 Launched for severe Acne (Adjunctive treatment) in USA (PO) - First Global Launch
- 28 Jul 2014 Registered for Acne (adjunctive treatment) in USA (PO, Tablet)